<p>Turn Therapeutics Inc.（纳斯达克代码：TTRX - 获取免费报告）董事 Arthur Golden 于 11 月 24 日星期一购买了 9,868 股 Turn Therapeutics 股票。该股票的平均购买成本为每股 3.44 美元，总交易额为 33,945.92 美元。收购完成后，该董事直接持有公司 60,602 股股票，估值约为 208,470.88 美元。此次交易使其持股增加了 19.45%。该交易已在证券交易委员会的法律文件中披露，相关信息可通过此链接获取。</p>
<p>获取 <strong>Turn Therapeutics</strong> 警报：</p>
<h2>Turn Therapeutics 价格表现</h2>
<p>TTRX 股票在周二下跌 0.20 美元，达到 3.30 美元。该公司的股票交易量为 82,657 股，而其平均交易量为 109,339 股。Turn Therapeutics Inc.的 1 年最低价为 2.57 美元，1 年最高价为 26.50 美元。</p>
<p>Turn Therapeutics（纳斯达克代码：TTRX - 获取免费报告）最近于 11 月 13 日星期四发布了季度财报。公司报告该季度每股收益为（0.07）美元。</p>
<h2>Turn Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>我们是一家制药和医疗器械开发公司，围绕一种专有平台技术构建，旨在增强药物性能。我们的专利混合工艺——商业上称为 PermaFusion™（“PermaFusion”）——能够在不使用乳化剂的情况下，将极性水溶性活性药物成分（“API”）稳定悬浮在油基载体中。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Turn Therapeutics</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>华纳兄弟出售传闻升温：投资者需要知道什么</li>
<li>什么是标准普尔 500 指数，它与其他指数有何不同</li>
<li>从科学项目到溶剂：WeRide 的 761% 收入激增</li>
<li>突破股票：它们是什么以及如何识别它们</li>
<li>标准普尔 500 指数在 12 月会反弹吗？这三个信号指向重大变动</li>
</ul>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Turn Therapeutics 吗？</h2>
<p>在考虑 Turn Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Turn Therapeutics 并不在名单上。</p>
<p>虽然 Turn Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TTRX

<p>Turn Therapeutics 董事 Arthur Golden 购买了 9,868 股，增加了 19.45% 的持股比例。该交易的价值为 33,945.92 美元，并在 SEC 备案中披露。股票价格下跌了 0.20 美元，至 3.30 美元，交易量为 82,657 股。Turn Therapeutics 报告的季度每股收益为（-0.07 美元）</p>

<p>Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden bought 9,868 shares of Turn Therapeutics stock in a transaction dated Monday, November 24th. The stock was purchased at an average cost of $3.44 per share, for a total transaction of $33,945.92. Following the completion of the acquisition, the director directly owned 60,602 shares of the company's stock, valued at approximately $208,470.88. The trade was a 19.45% increase in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink.</p>
<div class="lb-trans"><p>Turn Therapeutics Inc.（纳斯达克代码：TTRX - 获取免费报告）董事 Arthur Golden 于 11 月 24 日星期一购买了 9,868 股 Turn Therapeutics 股票。该股票的平均购买成本为每股 3.44 美元，总交易额为 33,945.92 美元。收购完成后，该董事直接持有公司 60,602 股股票，估值约为 208,470.88 美元。此次交易使其持股增加了 19.45%。该交易已在证券交易委员会的法律文件中披露，相关信息可通过此链接获取。</p>
</div><p>Get <strong>Turn Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Turn Therapeutics</strong> 警报：</p>
</div><h2>Turn Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Turn Therapeutics 价格表现</h2>
</div><p>Shares of TTRX stock traded down $0.20 on Tuesday, reaching $3.30. The company's stock had a trading volume of 82,657 shares, compared to its average volume of 109,339. Turn Therapeutics Inc. has a 1 year low of $2.57 and a 1 year high of $26.50.</p>
<div class="lb-trans"><p>TTRX 股票在周二下跌 0.20 美元，达到 3.30 美元。该公司的股票交易量为 82,657 股，而其平均交易量为 109,339 股。Turn Therapeutics Inc.的 1 年最低价为 2.57 美元，1 年最高价为 26.50 美元。</p>
</div><p>Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.07) EPS for the quarter.</p>
<div class="lb-trans"><p>Turn Therapeutics（纳斯达克代码：TTRX - 获取免费报告）最近于 11 月 13 日星期四发布了季度财报。公司报告该季度每股收益为（0.07）美元。</p>
</div><h2>Turn Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Turn Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.</p>
<div class="lb-trans"><p>我们是一家制药和医疗器械开发公司，围绕一种专有平台技术构建，旨在增强药物性能。我们的专利混合工艺——商业上称为 PermaFusion™（“PermaFusion”）——能够在不使用乳化剂的情况下，将极性水溶性活性药物成分（“API”）稳定悬浮在油基载体中。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Turn Therapeutics</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>Warner Bros. Sale Rumors Heat Up: What Investors Need to Know</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>From Science Project to Solvent: WeRide’s 761% Revenue Surge</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Will the S&amp;P 500 Rally in December? These 3 Signals Point to a Big Move Ahead</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Turn Therapeutics</li>
<li>什么是股息竞争者？投资股息竞争者</li>
<li>华纳兄弟出售传闻升温：投资者需要知道什么</li>
<li>什么是标准普尔 500 指数，它与其他指数有何不同</li>
<li>从科学项目到溶剂：WeRide 的 761% 收入激增</li>
<li>突破股票：它们是什么以及如何识别它们</li>
<li>标准普尔 500 指数在 12 月会反弹吗？这三个信号指向重大变动</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Turn Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Turn Therapeutics 吗？</h2>
</div><p>Before you consider Turn Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Turn Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Turn Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Turn Therapeutics 并不在名单上。</p>
</div><p>While Turn Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Turn Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Turn Therapeutics（NASDAQ:TTRX）的董事购买了价值 33,945.92 美元的股票